biosynex

Biosynex is a French laboratory that designs and distributes rapid diagnostic tests for various medical specialties. Learn about its history, products, news and acquisitions in the healthcare industry. Biosynex est un laboratoire français qui propose des solutions de santé adaptées aux différents réseaux de distribution (laboratoires, hôpitaux, pharmacies, etc.). Découvrez ses actualités, ses produits et ses services dans le domaine du diagnostic rapide. January 31, 2023 at 5:00 PM · 10 min read. Chembio Diagnostics, Inc.; Biosynex. Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth... Kit content: • 10 test cassette and pipettes • 20 lancets • 1 vial of buffer (2 mL) Detection of thrombosis (D-Dimer) in human plasma and whole blood. Cut-off 500 ng/mL FEU. BIOSYNEX MICRO-ALBMIN Kit content: • 20 strips in individual pouches • Color... Open the catalog to page 15 280K views 2 years ago. The Biosynex COVID-19 Ag Antigenic Self-testing Kit is a rapid, in vitro immunochromatography assay (also known as a lateral flow test) which allows for the qualitative ... The CE IVD-labeled Ag-RDST BIOSYNEX Antigen Self-Test COVID-19 Ag+ (Biosynex Swiss SA) is a rapid qualitative membrane-based immunochromatographic test that uses highly sensitive monoclonal antibodies to detect the SARS-CoV-2 N nucleocapsid protein in nasopharyngeal secretions sample. Specialising in the design and distribution of rapid diagnostic tests in France and in more than 90 countries, Biosynex, a French Laboratory, created in 2005, offers healthcare solutions that improve the overall treatment of patients. In close collaboration with healthcare professionals (pharmacists, laboratory technicians, doctors, hospitals ... Chembio Diagnostics Agrees to .2 Million Takeover by Biosynex; Shares Rise Pre-Bell. 2023. MT. Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million. 2023. CI. Biosynex SA entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. for .2 million. Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million. Biosynex SA entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. for .2 million. Biosynex SA completed the acquisition of 40% stakes in Theradiag SA. Biosynex SA acquired Doc2u SAS on October 12, 2022. BIOSYNEX COVID-19 Ag BSS. Qualitative detection of SARS-CoV-2 antigens in nasopharyngeal and nasal swabs. Type of sample: Nasopharyngeal and nasal. Time to result: 15 minutes. Content: 25 tests. Test format: Cassette. Reference : SW40006. Also available for automated reading and interpretation using the BSX READER®. BIOSYNEX COVID-19 Ag+ BSS. Biosynex conducted a tender offer by its wholly-owned indirect subsidiary, Project Merci Merger Sub, Inc. (“Purchaser”) for all of the issued and outstanding shares of common stock of Chembio. Biosynex designs, manufactures and distributes Rapid Diagnostic Tests (RDT) in France and internationally. The professional version of the RDTs allows better medical care for patients thanks to the speed of their results and their ease of use. About BIOSYNEX. Founded in 2005, French laboratory BIOSYNEX is a leading healthcare diagnostics group, specializing in rapid tests, monitoring of biotherapy and molecular diagnostics.